A next-generation CTLA-4 inhibitor, botensilimab ... the metrics must rise to meet the moment. “Our call to action to patients, to regulators, to pharma and biotech,” Dr. O’Day said ...

Hanx described the drug as a 'next-generation' immune-checkpoint inhibitor that represents a ‘breakthrough’ in cytotoxic T-lymphocyte–associated antigen 4 (CTLA ... any action on the basis ...

Among 13,568 patients with malignant melanoma, 145 were treated with PD1 inhibitors and 212 were treated with the CTLA-4 inhibitor ipilimumab. One year after starting treatment, 6.6% and 7.5% ...

Highlights Presentation Details: Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with ...

Opdivo is indicated for use in patients whose disease has progressed after treatment with BMS' CTLA-4 inhibitor Yervoy (ipilimumab) and - if the tumour is BRAF V600 mutation-positive - a BRAF ...